157 related articles for article (PubMed ID: 38554165)
21. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
23. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
24. Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
Alkrekshi A; Tamaskar I
Oncologist; 2021 May; 26(5):e827-e830. PubMed ID: 33655663
[TBL] [Abstract][Full Text] [Related]
25. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Han CL; Meng GX; Xue JS; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Int Immunopharmacol; 2023 Jan; 114():109519. PubMed ID: 36459922
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
[TBL] [Abstract][Full Text] [Related]
27. Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients.
Wan L; Wu C; Wu Q; Luo S; Liu J; Xie X
Cancer Med; 2023 Jan; 12(2):1841-1849. PubMed ID: 35770869
[TBL] [Abstract][Full Text] [Related]
28. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
29. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
30. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy.
Pan S; Yu Y; Wang S; Tu B; Shen Y; Qiu Q; Liu X; Su N; Zuo Y; Luan J; Zhang JY; Shi M; Meng F; Wang FS
Front Immunol; 2022; 13():892618. PubMed ID: 35711409
[TBL] [Abstract][Full Text] [Related]
31. Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Wang Y; Lau W; Li Y; Tian Y; Lei Y; Wang J; Xia F
Int J Surg; 2023 Nov; 109(11):3590-3601. PubMed ID: 37598406
[TBL] [Abstract][Full Text] [Related]
32. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
33. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
Front Oncol; 2022; 12():795933. PubMed ID: 35223476
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of addition immune checkpoint inhibitors to chemotherapy as first-line treatment for small cell lung cancer patients with liver or brain metastases: a systematic review and meta-analysis.
Chen CR; Qi WX; Liu T; Tong X
Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5857-5867. PubMed ID: 36066161
[TBL] [Abstract][Full Text] [Related]
35. Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?
Wu Q; Luo S; Xie X
J Immunother; 2022 Sep; 45(7):307-320. PubMed ID: 35674663
[TBL] [Abstract][Full Text] [Related]
36. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
[TBL] [Abstract][Full Text] [Related]
37. Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Shen J; Hou H; Liang B; Guo X; Chen L; Yang Y; Wang Y
Front Immunol; 2023; 14():1155104. PubMed ID: 37153578
[TBL] [Abstract][Full Text] [Related]
38. Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?
De Keukeleire SJ; Vermassen T; Nezhad ZM; Kerre T; Kruse V; Vlierberghe HV; Vermaelen K; Rottey S
Immunotherapy; 2021 Apr; 13(5):409-418. PubMed ID: 33487052
[TBL] [Abstract][Full Text] [Related]
39. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
Shah NJ; Al-Shbool G; Blackburn M; Cook M; Belouali A; Liu SV; Madhavan S; He AR; Atkins MB; Gibney GT; Kim C
J Immunother Cancer; 2019 Dec; 7(1):353. PubMed ID: 31847881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
